Big Pharma Split Corp Class A (PRM) - Total Assets
Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) holds total assets worth CA$25.77 Million CAD (≈ $18.64 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Big Pharma Split Corp Class A reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Big Pharma Split Corp Class A - Total Assets Trend (2017–2024)
This chart illustrates how Big Pharma Split Corp Class A's total assets have evolved over time, based on quarterly financial data. Explore Big Pharma Split Corp Class A long-term investment allocation to see how much of total assets are deployed in long-term investments.
Big Pharma Split Corp Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Big Pharma Split Corp Class A's total assets of CA$25.77 Million consist of 4.3% current assets and 95.7% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 3.9% |
| Accounts Receivable | CA$96.74K | 0.4% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Big Pharma Split Corp Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PRM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Big Pharma Split Corp Class A's current assets represent 4.3% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 5.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Big Pharma Split Corp Class A Competitors by Total Assets
Key competitors of Big Pharma Split Corp Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Metrics Master Income Trust
AU:MXT
|
Australia | AU$2.46 Billion |
|
Jpmorgan Global Core Real Assets Ltd
LSE:JARA
|
UK | GBX70.85 Million |
|
Northern Trust Corporation
NASDAQ:NTRS
|
USA | $174.57 Billion |
|
Principal Financial Group Inc
NASDAQ:PFG
|
USA | $332.70 Billion |
|
Industrivarden AB ser. C
ST:INDU-C
|
Sweden | Skr211.38 Billion |
|
Sprott Physical Gold and Silver Trust
TO:CEF
|
Canada | CA$9.34 Billion |
|
Anxin Trust Co Ltd
SHG:600816
|
China | CN¥26.40 Billion |
|
Norte Grande
SN:NORTEGRAN
|
Chile | CL$2.96 Billion |
Big Pharma Split Corp Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.21 | 2.58 | 2.03 |
| Quick Ratio | 0.21 | 2.58 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-9.96 Million | CA$16.89 Million | CA$12.97 Million |
Big Pharma Split Corp Class A - Advanced Valuation Insights
This section examines the relationship between Big Pharma Split Corp Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | CA$26.30 Million |
| Market Capitalization | $11.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Big Pharma Split Corp Class A's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Big Pharma Split Corp Class A's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Big Pharma Split Corp Class A (2017–2024)
The table below shows the annual total assets of Big Pharma Split Corp Class A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$26.30 Million ≈ $19.03 Million |
-0.88% |
| 2023-12-31 | CA$26.53 Million ≈ $19.19 Million |
-32.13% |
| 2022-12-31 | CA$39.10 Million ≈ $28.28 Million |
+3.39% |
| 2021-12-31 | CA$37.81 Million ≈ $27.35 Million |
+64.89% |
| 2020-12-31 | CA$22.93 Million ≈ $16.59 Million |
-15.62% |
| 2019-12-31 | CA$27.18 Million ≈ $19.66 Million |
-19.19% |
| 2018-12-31 | CA$33.63 Million ≈ $24.33 Million |
+3.52% |
| 2017-12-31 | CA$32.49 Million ≈ $23.50 Million |
-- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.